The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin, plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma.
Thomas J. George
Consultant or Advisory Role - Regeneron
Research Funding - Bayer; Bristol-Myers Squibb
Alison Marguerite Ivey
No relevant relationships to disclose
Karen Colleen Daily
No relevant relationships to disclose
Long H. Dang
No relevant relationships to disclose
Scott Watson
No relevant relationships to disclose
Renee Granicz
No relevant relationships to disclose
Kevin Tormes
No relevant relationships to disclose
Xiaomin Lu
No relevant relationships to disclose
Chen Liu
No relevant relationships to disclose
Carmen Joseph Allegra
No relevant relationships to disclose
Kevin Behrns
No relevant relationships to disclose
Steven J. Hughes
No relevant relationships to disclose
Olorunseun Olatunji Ogunwobi
No relevant relationships to disclose
Jose Gilberto Trevino
No relevant relationships to disclose